DRUG-RESISTANCE AND HETEROGENEOUS LONG-TERM VIROLOGICAL RESPONSES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED SUBJECTS TO ZIDOVUDINE AND DIDANOSINE COMBINATION THERAPY

被引：88

作者：

SHAFER, RW ^{[1
]}

IVERSEN, AKN ^{[1
]}

WINTERS, MA ^{[1
]}

AGUINIGA, E ^{[1
]}

KATZENSTEIN, DA ^{[1
]}

MERIGAN, TC ^{[1
]}

机构：

[1] STANFORD UNIV,MED CTR,DIV INFECT DIS & GEOG MED,STANFORD,CA 94305

来源：

JOURNAL OF INFECTIOUS DISEASES | 1995年 / 172卷 / 01期

关键词：

D O I：

10.1093/infdis/172.1.70

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Plasma human immunodeficiency virus (HIV) type 1 RNA levels, CD4 lymphocyte changes, and drug resistance were studied in HIV-infected patients with 200-500 CD4 lymphocytes/mu L who received zidovudine and didanosine combination therapy for 2 years. Among 35 patients, 10 had sustained and 16 had transient >10-fold reductions in HIV RNA; 9 did not have 10-fold HIV RNA reductions. Only patients with sustained HIV suppression maintained increased CD4 cell counts for 2 years (370 to 501 cells/mu L; P = .006). Patients with transient HIV suppression were more likely to develop drug-resistant HIV strains (12/16 vs. 5/19, P = .01) and reverse transcriptase (RT) mutations (4.5 vs. 2.5/strain; P = .02) than were patients with sustained or no HN suppression. Zidovudine resistance occurred with RT mutations at codons 41, 67, 70, 215, and 219. Multidrug resistance occurred with mutations at codons 62, 75, 77, 116, and 151. Mutations occurred at codons 60, 68, 118, 210, and 228 in greater than or equal to 4 patients each. Heterogeneity exists among individual virologic responses to zidovudine and didanosine combination therapy. HIV resistance mechanisms during combination therapy appear more complex than reported with monotherapy.

引用

页码：70 / 78

页数：9

共 31 条

[1] Hirsch M.S., D' Aquila R.T., Therapy for human immunodeficiency virus infection, N Engl J Med, 328, (1993)
[2] Sande M.A., Carpenter C., Cobbs C.G., Holmes K.K., Sanfrod J.P., Antiretroviral therapy for adult hiv-infected patients: Recommendations from a state-of-the-art conference, JAMA, 270, pp. 2583-2589, (1993)
[3] Richman D.D., Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents, Antimicrob Agents Chemother, 37, pp. 1207-1213, (1993)
[4] Erice A., Balfour H.H., Resistance of human immunodeficiency virus type 1 to antiretroviral agents: A review, Clin Infect Dis, 18, pp. 149-156, (1994)
[5] Tudor-Williams G., St Clair M.H., Mc Kinney R.E., Et al., Hiv-1 sensitivity to zidovudine and clinical outcome in children, Lancet, 339, pp. 15-19, (1992)
[6] Kozal M.J., Shafer R.W., Winters M.A., Katzenstein D.A., Merigan T.C., A mutation in human immunodeficiency virus reverse transcriptase and decline in cd4 lymphocyte numbers in long-term zidovudine recipients, J Infect Dis, 167, pp. 526-532, (1993)
[7] Montaner J., Singer J., Schecter M.T., Et al., Clinical correlates of in vitro hiv-1 resistance to zidovudine. Results of the multicenter canadian azt trial, AIDS, 7, pp. 189-196, (1993)
[8] Ogino M.T., Dankner W.M., Spector S.A., Development and significance of zidovudine resistance in children infected with human immunodeficiency virus, J Pediatr, 123, pp. 1-8, (1993)
[9] St Clair M.H., Martin J.L., Tudor-Williams G., Et al., Resistance to ddl and sensitivity to azt induced by a mutation in hiv-1 reverse transcriptase, Science, 253, pp. 1557-1559, (1991)
[10] Larder B.A., 3'-azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnuclcoside reverse transcriptase inhibitors, Antimicrob Agents Chemother, 36, pp. 2664-2669, (1992)

← 1 2 3 4 →